Economic Evaluation of Iron Chelation Agents: Oral Deferasirox versus Infusional Deferoxamine.
- Author:
Jin Hyun KIM
1
;
Youn Hee KIM
Author Information
- Publication Type:Original Article ; Clinical Trial
- Keywords: Deferasirox; Deferoxamine; Iron chelating agents; Cost analysis; Cost utility analysis
- MeSH: Benzoates; Compliance; Cost Savings; Costs and Cost Analysis; Deferoxamine; Humans; Income; Infusions, Subcutaneous; Iron; Iron Chelating Agents; Iron Overload; Quality of Life; Triazoles
- From:Korean Journal of Hematology 2008;43(2):89-97
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Patients with transfusional iron overload have relied on treatment with deferoxamine, a standard chelating agent. Deferoxamine is administered by intravenous or subcutaneous infusion over an 8~12 hour period 5~7 times per week; however, administration of deferoxamine may lead to poor compliance and reduced quality of life in patients. The use of deferasirox, a once daily oral chelation agent, was recently approved. We conducted an economic evaluation of these two iron-chelating medications in transfusion-dependent patients. METHODS: The efficacy of oral deferasirox and infusion deferoxamine was assumed equal based on clinical trials of non-inferiority with the administration of 20mg/kg/day deferasirox versus 40mg/kg/day deferoxamine. Depending on the methods utilized for measuring administration time, travel time and convenience between the use of infusion and oral therapy, either cost analysis or cost-utility analysis was undertaken, respectively. Cost analysis included determination of direct medical costs (drug costs and administration costs), non-medical costs (travel costs), and indirect costs (productivity loss associated medical utilization). For cost utility analysis, the cost per QALYs (quality-adjusted life years) was calculated based on costs subtracting indirect costs (productivity loss) and gains of QALYs between the two agents. RESULTS: Deferasirox therapy resulted in a cost savings per patient of 23,471,777 Korean won based on cost analysis. Based on cost utility analysis, the cost per QALYs gained was -398,576 Korean won (4,527,819 Korean won savings with a gain of 11.5 QALYs per patient). CONCLUSION: The results of cost analysis and cost utility analysis of the use of oral deferasirox versus infusion deferoxamine showed that deferasirox is a more economical and potentially socially beneficial iron-chelating agent in Korea.
